Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2807528 | 0.84 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2NPSR1APLNR | |
| SCHEMBL14864801 | 0.84 | SMN1; SMN2 (0.33) | CNR2ALDH1A1SMN1; SMN2PIK3CD | |
| SCHEMBL16461184 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2 | |
| SCHEMBL205844 | 0.76 | PYGL (0.38) | ALDH1A1 | |
| SCHEMBL2708029 | 0.76 | PYGL (0.38) | ALDH1A1 | |
| SCHEMBL204476 | 0.76 | PYGL (0.38) | ALDH1A1 | |
| SCHEMBL14864803 | 0.75 | CA12 (0.42) | ALDH1A1SMN1; SMN2PIK3CD | |
| SCHEMBL12174947 | 0.75 | CA12 (0.42) | ALDH1A1SMN1; SMN2PIK3CD | |
| SCHEMBL18526787 | 0.75 | CA12 (0.42) | ALDH1A1SMN1; SMN2PIK3CD | |
| SCHEMBL1200716 | 0.73 | CTSK (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | CNR2 4830/4885L3MBTL1 2200/4885ALDH1A1 3957/4885 |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CNR2 4830/4885L3MBTL1 2200/4885ALDH1A1 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.